The intervention of cannabinoid receptor in chronic and acute kidney disease animal models: a systematic review and meta-analysis.

"Declarations Ethics approval and consent to participateAn ethics statement is not applicable because this study is based exclusively on published literature. Consent for publicationNot applicable. Competing interestsThe authors declare that they have no competing interests. Competing interests The authors declare that they have no competing interests."

"Funding This work was supported by the National Natural Science Foundation of China (No.81970633) and Natural Science Foundation of Henan Province (No. 222300420330)."

"All articles acquired by the search were reviewed, and irrelevant publications were removed by scanning the title and abstract. The selected articles were further assessed by full-text reading. Two investigators independently (Z. Z. and J.D.) achieved the study selection, with any differences determined by common discussion and judgment of a third reviewer (D.L.), if consensus was not reached. Studies that conformed to the following criteria were considered possibly qualified: (1) Animal models of acute and chronic kidney disease; (2) modulators of cannabinoid receptors (including agonists and antagonists) or genetic modifications of CB1 or CB2 were used as interventions, with corresponding control groups set up; (3) The primary outcomes were albuminuria, blood urea nitrogen (BUN), serum creatinine (Scr), kidney weight/body weight ratio (KW/BW) and pathology of renal tissue, and (4) the secondary outcomes were blood glucose, body weight (BW), mechanistic pathway indicators of cannabinoid receptor system involved in kidney tissue injury. Human studies, in vertebrate animal and in vitro, ex vivo experimental studies will be excluded. The protocol of this meta-analysis was registered in the International Prospective Register of Systematic Reviews (PROSPERO) (CRD42021272950)."